Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XF-73 Nasal Gel for S. aureus Colonization in Surgical Patients
NCT03915470Phase 2Completed
- Sponsor
- Destiny Pharma
- Start
- Aug 2019
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of exeporfinium chloride in staphylococcal infection, surgical site infection (SSI), sponsored by Destiny Pharma. Started Aug 2019; status: completed.
02
Drugs
exeporfinium chloride
03
Conditions
staphylococcal infectionsurgical site infection (SSI)
Beyond the preview
Go deeper on NCT03915470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03915470.